REFRACTORY ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Clinical trials for REFRACTORY ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE trials appear
Sign up with your email to follow new studies for REFRACTORY ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising new combo targets tough infant leukemia
Disease control OngoingThis study tests a new oral drug (revumenib) combined with chemotherapy in infants and young children up to 6 years old whose leukemia has returned or not responded to treatment. The leukemia must have a specific genetic change called KMT2A rearrangement. The goal is to see if th…
Matched conditions: REFRACTORY ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug combo offers hope for kids with tough leukemia
Disease control OngoingThis early-stage study tests the safety and best dose of two drugs, selinexor and venetoclax, when given with standard chemotherapy to children and young adults whose acute myeloid leukemia (AML) has returned or not responded to treatment. About 37 participants will receive the c…
Matched conditions: REFRACTORY ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 13, 2026 16:04 UTC